Pink SheetThe US Food and Drug Administration’s June user fee goal calendar reflects the gravitational pull of major meetings. The month opens with the monster American Society of Clinical Oncology annual meeti
ScripIonis’s RNA-targeting medicine Tryngolza (olezarsen) has met its primary endpoints in a trial to lower triglycerides in patients with moderate hypertriglyceridemia with or at risk for atherosclerotic
ScripThe first clinical data from CRISPR Therapeutics’ in vivo gene-editing candidate, CTX310, look promising, with steep drops in low-density lipoprotein (LDL)-cholesterol and triglyceride levels. The r
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C